Cite

HARVARD Citation

    Lowe, J. et al. (2020). Mineralocorticoid receptor antagonism by finerenone is sufficient to improve function in preclinical muscular dystrophy. ESC heart failure. pp. 3983-3995. [Online]. 
  
Back to record